Virax Biolabs Shares Surge on Exclusive Fosun Distribution Deal for Southeast Asia
Virax Biolabs (VRAX) shares more than doubled on July 9, 2026, after signing an exclusive commercial supply agreement with Fosun Diagnostics for its ImmuneSelect immune profiling products. The deal covers six Southeast Asian markets: Thailand, Vietnam, Indonesia, Philippines, Singapore, and Malaysia. Initial rollout targets tuberculosis research in Thailand, with volume-based pricing and potential expansion into additional products and OEM partnerships. The stock surged up to 228%, though it remains down year-to-date amid dilution concerns.
Editorial summary awaiting refresh
Cross-source coverage
Wire timeline
Virax Biolabs enters immune profiling product supply deal with Fosun
Virax Biolabs Group, through its UK subsidiary, has signed an exclusive commercial supply agreement with Fosun Diagnostics to provide its ImmuneSelect immune profiling product line across six Southeast Asian countries: Indonesia, Malaysia, the Philippines, Singapore, Thailand, and Vietnam. The deal covers research-use-only ELISpot assay plates that measure cellular immune responses, with initial focus on tuberculosis-related research in Thailand, where Fosun has identified immediate customer interest. The agreement includes structured, volume-based pricing tiers and allows for immediate product supply upon purchase orders. It provides a framework for phased expansion, potentially including additional products, larger-scale supply, and OEM or private-label arrangements. The exclusivity is tied to minimum purchase and performance criteria. Virax Biolabs CEO James Foster called it a major step for commercial rollout in Southeast Asia, while Fosun MedTech's Leon Zhang expressed interest in evaluating the ELISpot platform across regional markets.
Yahoo FinanceVirax Biolabs enters immune profiling product supply deal with Fosun
Virax Biolabs Group, through its UK subsidiary, has signed an exclusive commercial supply agreement with Fosun Diagnostics, a key entity under Fosun Medtech (a Fosun Pharma division), for its ImmuneSelect immune profiling product line. The deal covers six Southeast Asian countries: Indonesia, Malaysia, the Philippines, Singapore, Thailand, and Vietnam. It allows immediate product supply based on purchase orders and aims to boost near-term revenue and regional growth. Virax will provide ImmuneSelect ELISpot assay plates for measuring cellular immune responses, with structured volume-based pricing. The initial focus is on tuberculosis-related research in Thailand, where Fosun has identified customer interest and begun evaluations through its regional network. The agreement includes potential expansion to additional products, larger-scale supply, and OEM or private-label arrangements, with exclusivity tied to minimum purchase and performance criteria.
Yahoo FinanceVirax Biolabs enters immune profiling product supply deal with Fosun
Virax Biolabs Group subsidiary Virax Biolabs (UK) has signed an exclusive commercial supply agreement with Fosun Diagnostics for its research-use-only ImmuneSelect immune profiling product line. Fosun is the key entity of the diagnostics business under Fosun Medtech, a Fosun Pharma division. The agreement covers six Southeast Asian countries: Indonesia, Malaysia, the Philippines, Singapore, Thailand and Vietnam. It allows for immediate product supply in response to purchase orders and aims to support near-term revenue prospects and regional business growth. Under the agreement, Virax Biolabs will provide ImmuneSelect products, which include ELISpot assay plates used to measure cellular immune responses, to Fosun Diagnostics based on structured, volume-based pricing tiers. The collaboration initially focuses on tuberculosis-related research applications in Thailand, where Fosun has identified immediate customer interest and begun evaluation activities through Fosun Pharma's regional network. This rollout could later extend across other countries in the region. The deal provides a framework for phased expansion that may include additional products, larger-scale supply, and potential original equipment manufacturer (OEM) or private-label arrangements. The exclusivity of the agreement is related to minimum purchase and performance criteria.
Yahoo FinanceVirax Biolabs Stock Skyrockets 100% on Exclusive Distribution Agreement
Virax Biolabs (VRAX) shares surged 100% on July 9, 2026, after announcing an exclusive commercial supply agreement with Fosun Diagnostics, a subsidiary of Fosun Pharma. The deal opens six ASEAN markets (Thailand, Vietnam, Indonesia, Malaysia, Singapore, Philippines) for Virax's ImmuneSelect T-cell immune profiling products. The agreement is purchase-order-driven, creating near-term revenue potential with volume-based pricing tiers. However, the stock remains down over 25% year-to-date. Virax also announced a $3.3 million options-exercise deal at a discounted $6 per share, issuing up to 2.1 million new warrants, introducing dilution risk. The company recently executed a 1-for-25 reverse stock split to maintain Nasdaq listing. Only two Wall Street firms cover VRAX, rating it 'Moderate Buy' with a mean price target of $25, underscoring limited institutional conviction.
Yahoo FinanceVirax Biolabs Stock Triples After Signing Multi-Country Supply Deal with Fosun Diagnostics
Virax Biolabs Group Limited (NASDAQ: VRAX) saw its stock surge over 228% in a single session after announcing a multi-country commercial supply agreement with Fosun Diagnostics for its ImmuneSelect product line. The exclusive deal covers six Southeast Asian markets: Thailand, Vietnam, Indonesia, the Philippines, Singapore, and Malaysia, with immediate product supply under purchase orders. The partnership is expected to drive near-term revenue and regional expansion, particularly for tuberculosis-related research in Thailand. Virax Biolabs develops in vitro diagnostic technologies for viral and immune-mediated diseases, focusing on post-acute infection syndromes including Long COVID. The company recently completed a 1-for-25 share consolidation and reported positive early pilot data for its ViraxImmune blood-based test, which showed 88% specificity and 92% positive predictive value in distinguishing patients from healthy controls.
Yahoo FinanceVirax Biolabs Shares Double After Exclusive Fosun Distribution Agreement
Virax Biolabs Group Limited (NASDAQ:VRAX) saw its shares double on July 9, 2026, after announcing an exclusive commercial supply agreement with Fosun Diagnostics for its ImmuneSelect immune profiling product portfolio. The agreement covers six Southeast Asian markets: Thailand, Vietnam, Indonesia, the Philippines, Singapore, and Malaysia. It establishes a framework for immediate product shipments through purchase orders, creating near-term revenue opportunities. The initial rollout will target tuberculosis-related research applications in Thailand, where Fosun has identified immediate customer demand. The pricing structure includes volume-based tiers to support scalable expansion across the ASEAN region. Beyond the initial supply arrangement, the framework allows for expansion into additional product lines, larger-volume supply agreements, and potential OEM or private-label partnerships. Fosun Diagnostics is part of Fosun Pharma, which reported revenue of approximately $5.8 billion in 2025.
Yahoo Finance